The strong clinical data in two distinct autoimmune indications supports miv-cel's potential as a best-in-class therapy. Monitor upcoming regulatory interactions and the progression of the Phase 3 gMG trial for further validation of the clinical benefit.
Price Chart
Executive Summary
Kyverna Therapeutics announced positive clinical data from two trials: the primary analysis of its registrational trial KYSA-8 in Stiff Person Syndrome (SPS) and longer-term follow-up data from its Phase 2 trial KYSA-6 in generalized Myasthenia Gravis (gMG). The data showed significant improvements in key endpoints, including mobility and disability scores for SPS and clinical outcomes for gMG, with a well-tolerated safety profile.
Key Facts
- SPS trial (KYSA-8) met primary endpoint: 46% median improvement in T25FW at Week 16, with 81% of patients achieving clinically meaningful improvement.
- All 26 SPS patients were free of immunomodulatory therapies for SPS as of Week 16 and through last follow-up.
- gMG trial (KYSA-6) showed substantial and clinically meaningful reductions in MG-ADL and QMG scores sustained out to 52 weeks.
- 100% of gMG patients were free of immunotherapies, including NSISTs, high-dose steroids (>10 mg), and FcRn and complement inhibitors up to 24 weeks.
- Miv-cel demonstrated a well-tolerated safety profile with no high-grade CRS or ICANS observed in both trials.
Financial Impact
The data supports the potential for miv-cel to become the first approved autoimmune CAR T therapy, with BLA submission preparations underway for SPS and a Phase 3 gMG trial advancing.
Risk Factors
- Regulatory approval is not guaranteed despite positive data.
- Long-term safety and efficacy data beyond 52 weeks are still needed.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-168287 |
| Document: d100817d8k.htm | 0001193125-26-168287 |
| Document: 0001193125-26-168287-index-headers.html | 0001193125-26-168287 |
| Document: 0001193125-26-168287-index.html | 0001193125-26-168287 |
| Document: 0001193125-26-168287.txt | 0001193125-26-168287 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | SC 13G | $5.83 $6.04 | ▲ +3.60% | ▲ +3.27% | $5.25 (−9.95%) |
Sep 24, 2026 4w ago | 8-K | $6.99 $6.81 | ▼ −2.58% | ▼ −3.12% | $5.25 (−24.89%) |
Aug 11, 2026 10w ago | 8-K | $8.05 $8.08 | ▲ +0.37% | ▼ −0.33% | $5.25 (−34.78%) |
Aug 11, 2026 10w ago | Press Release | $8.05 $8.08 | ▲ +0.37% | ▼ −0.33% | $5.25 (−34.78%) |
Jul 27, 2026 13w ago | 8-K | $7.92 $7.49 | ▼ −5.43% | ▼ −5.67% | $5.25 (−33.71%) |
Jul 9, 2026 15w ago | 8-K | $9.81 $8.49 | ▼ −13.51% | ▼ −13.94% | $5.25 (−46.48%) |
Jun 11, 2026 19w ago | Institutional Cluster | $8.06 $8.15 | ▼ −1.18% | ▲ +0.58% | $5.25 (+34.82%) |
May 4, 2026 25w ago | 8-K | $9.00 $9.21 | ▲ +2.33% | ▲ +1.54% | $5.25 (−41.67%) |
Apr 22, 2026 26w ago | 8-K | $10.23 $8.95 | ▼ −12.51% | ▼ −12.12% | $5.25 (−48.68%) |
Apr 20, 2026 27w ago | Press Release | $11.25 $9.71 | ▼ −13.69% | ▼ −13.04% | $5.25 (−53.33%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers